Blocking the PSGL-1/VISTA interaction using an anti-VISTA antibody significantly inhibited LUSC tumor growth in wild-type but not mTORC2-deficient tumors, suggesting that targeting the mTORC2-PSGL-1-VISTA pathway may offer a new therapeutic avenue for LUSC. This evidence concerns the gene VSIR and neoplasm.